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Broad Toll-like receptor 9 (TLR9) signalling defects after CpG in vitro stimulation have been described in common variable
immunodeﬁciency (CVID). CXCL16, a surface receptor, was recently shown to inﬂuence cell responses to CpG. We evaluated
the expression and function of CXCL16 on B cells from healthy controls and CVID patients. We report that CXCL16 is normally
expressed on B cells throughout peripheral maturation. Decreased B cell expression of CXCL16 was observed in a subgroup of
CVID patients that correlated with defective in vitro responses to CpG (such as upregulation of CD69, CD86, AICDA, IL-6, and
TLR9). Our data suggest that expression levels of a surface receptor, namely, CXCL16, correlate with B cell responses mediated by
TLR9 in common variable immunodeﬁciency.
1.Introduction
Common variable immunodeﬁciency (CVID) is the most
common symptomatic primary immunodeﬁciency [1–4].
Defective B cell maturation in memory B cells and plasma
cells is largely accredited to represent the main pathogenetic
mechanism resulting in hypogammaglobulinemia and con-
sequently recurrent infections in the aﬀected patients.
Clinical manifestations may also include autoimmune phe-
nomena, splenomegaly and lymphomas [2, 3, 5]. Genetic
causes are only known in 10–12% of patients, underlying
the important heterogeneity and complexity of this disorder.
Disease-causing mutations in ICOS, CD19, CD81, and
disease-predisposing mutations in TACI, BAFF-R, and CD20
have been reported in a minority of CVID patients [6–12].
Of note, with the exception of ICOS, all of these aﬀect B cell
speciﬁcgenes,inkeepingwiththenotionthatimpairedBcell
homeostasis is a hallmark of CVID.
In recent years, the importance of components of the
innate immune system, namely, Toll-like receptor family
members (TLRs), was underlined and a direct link between
innate and adaptive immunity was established. TLR9 in
particular, selectively expressed in the cytoplasm of B cells,
promotes B cell activation and maturation in response
to CpG (oligodeoxynucleotides: oligonucleotides containing
selected CpG-DNA sequences) stimulation in vitro [13].
In vitro studies showed that CVID patients presented pro-
found defects in response to in vitro CpG stimulation. In
particular, CVID B cells presented defective upregulation
of CD86 after CpG stimulation, failed to increment IL-6
and IL-10 production, and failed to upregulate activation-
induced cytosine deaminase (AICDA) [14, 15]. However,
the molecular mechanisms underlying impaired response to
CpG in patients with CVID remain undeﬁned.
Recent studies have suggested that the interaction be-
tween CXCL16 and CXCR6 might inﬂuence the inﬂamma-
tory responses and the magnitude of the immune response
to CpG by speciﬁcally inﬂuencing the cellular uptake, sub-
cellular localization, and cytokine proﬁle [16].
So far, CXCL16 has been reported to be present in a
membrane bound and a soluble form and appears to have
multiple roles: it functions as an endocytic receptor, as2 The Scientiﬁc World Journal
Table 1: Summary of the clinical and immunological features of CVID patients included in this study (age of onset, immunoglobulin serum
levels at diagnosis, percentage of CD19 positive B cells, and presence/absence of autoimmune manifestations and splenomegaly).
Age of onset (years) IgG (mg/dL) IgA (mg/dL) IgM (mg/dL) CD19 (%) Autoimmunity Splenomegaly
Patient 1 3 274 22 25 18 n n
Patient 2 1 160 4 22 24 n y
Patient 3 40 313 2 37 15 n y
Patient 4 1 239 46 18 24 n n
Patient 5 7 408 4 17 12 n n
Patient 6 6 62 367 180 18 n y
Patient 7 3 69 6 14 12 n y
Patient 8 2 330 26 10 25 n y
Patient 9 13 495 9 7 2 n n
Patient 10 7 160 14 14 3 y n
Patient 11 9 432 184 24 2 n y
Patient 12 21 463 2 263 11 n n
Patient 13 34 59 1 20 10 n n
Patient 14 1 291 5 6 20 n y
Patient 15 24 85 4 16 2 y y
Median 7 256 6 18 12
an adhesion molecule, and as a chemokine which binds
the orphan G-protein receptor CXCR6 [17]. Several func-
tions have been attributed to membrane-bound CXCL16.
Through its chemokine domain, it promotes adhesion and
phagocytosis of both Gram-positive and Gram-negative bac-
teria, as well as chemotaxis of T and NKT cells [18]. CXCL16
is expressed by diﬀerent cell types such as monocytes, pDCs,
smooth muscle cells, while the expression on B cells is not
wellcharacterizedyet[19].ThereceptorCXCR6ontheother
hand is expressed by diﬀerent T cell subsets, namely, CD8
T cells and CD4 eﬀector memory and central memory T
cells, but not na¨ ıve CD4 T cells [20]. In light of the role of
CXCL16 in modulating cellular responses to CpG, and of
the demonstration that B lymphocytes from CVID patients
have an impaired response to CpG, we have assessed the
expression of CXCL16 on the surface of B lymphocytes from
CVID patients and correlated such expression with CVID B
cell responses to CpG.
The molecular basis of defective B cell responses to CpG
in CVID remains unknown. We hypothesized that in vitro
B cell responses to CpG stimulation in CVID may be depen-
dentonCXCL16.OurdataprovideevidencethatCVIDBcell
responses to CpG correlate with CXCL16 expression levels.
2.MaterialsandMethods
2.1. Patients. Fifteen patients aﬀected with CVID were in-
cluded in this study; male to female ratio was close to 1:1
(8 male versus 7 female). Summary of patients’ clinical and
immunological characteristics is shown in Table 1.D i a g -
nosis of CVID was made according to the ESID criteria
(http://www.esid.org/). CVID patients are under regular fol-
lowup at the Outpatient Clinic of the Pediatric Immunology
and Rheumatology Unit, Children’s Hospital, Brescia, Italy.
All patients were under regular immunoglobulin replace-
ment therapy. This study was conducted in accordance
with the guidelines of the World Medical Association’s Dec-
laration of Helsinki (most recent revision). This study
was reviewed and approved from the Hospital’s Ethical
Committee.Informedconsentwasobtainedfromallpatients
and healthy controls (matched for age and sex).
2.2. Primers, PCR, and Genetic Sequencing. Primers were
designed including the ﬂanking regions of exons 1 to 5 of
the CXCL16 encoding gene (available upon request). PCR
products were then puriﬁed, and direct gene sequencing of
all exons of the CXCL16 gene was performed using an ABI
PRISM 310 sequencer. Sequences were analyzed using the
Sequence Navigator software (SeqScape v2.6).
2.3. Cell Separation, Cell Stimulation, Flow Cytometry, and
Real Time PCR. PBMCs from healthy controls and CVID
patients were separated from peripheral whole blood sam-
ples using Ficoll (Lympholyte H sterile liquid, Cedarlane
Diagnostics). Tonsillar B cells were isolated from healthy
tonsils after tissue digestion, Ficoll separation, and B cell
separation (Easy Sep Human Enrichment Kit, Stem Cell).
Cell separation eﬃciency was veriﬁed by ﬂow cytometry
with B cell purity >90%. Cells were cultured in 96-well
plates (200.000 cells per well) in RPMI added with 10% FCS
(EuroClone), Penicillin-Streptomycin (EuroClone), and L-
Glutamine (EuroClone) in the presence or absence of CpG
ODN 2216 (Labogen) at a ﬁnal concentration of 0.5μM.
Cells were harvested at time 0 and after 24-hour incubation
with or without CpG, washed with PBS 1% FCS, and
then marked with speciﬁc antibodies (CD19-PerCP, CD20-
PerCP, CD27-PE, IgD-FITC, CD69-FITC, CD86-PE)(BD,
Becton Dickinson), incubated for 20 minutes at 4◦C, washed
twice, and then acquired with a FACS-Calibur Cytometer
(BD). CXCL16 expression was evaluated using a biotinylated
CXCL16 monoclonal antibody (incubated for 20 minutes
at 4◦C, washed twice) followed by a secondary stainingThe Scientiﬁc World Journal 3
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Figure 1: CXCL16 expression on primary B cells. (a) CXCL16 expression on tonsillar CD19+ B cells and peripheral CD19+Bc e l ls u b s e t s
from healthy control (representative experiment). (b) Histogram-depicting percentage and mean ﬂuorescence intensity of CXCL16+ CD19+
tonsillar B cells and peripheral B cells from healthy donors (mean of three diﬀerent experiments for tonsillar B cells and ten healthy controls
for peripheral B cells). (c) CXCL16 expression in the diﬀerent maturative stages of peripheral B cells (representative of three diﬀerent
experiments).
with streptavidin-PE or streptavidin-APC (incubated for 20
minutes at 4◦C, washed twice). Flow cytometric analysis was
performed using the Flowjo software. In alternative, after
24 hours of incubation with or without CpG, total RNA
was extracted and Real-Time PCR was performed for Tlr-9,
Aicda, Il-6 genes, according to the manufacturer’s protocol
(Applied Biosystems). For the TNF-α blockade experiments,
cells were incubated with monoclonal anti-TNF-α for 48
hours at 50ug/mL and then CpG was added as above. Real
Time PCR was analyzed with the ABI PRISM 7000 SDS
software.
2.4. Statistical Analysis. The χ2 test was used for the analysis
of the allelic frequencies, for the CXCL16 expression levels
and Real-Time experiments between CVID patients and
healthy controls. The ﬁndings were considered signiﬁcant
when the P value was lower than 0.001 (P<0.001).
3. Results
3.1. CXCL16 Expression on Primary B Cells. CXCL16 expres-
sionhasbeendescribedinvariouscelltypessuchasdendritic
cells, macrophages, podocytes, and others; however, its
expression on B cells has not been clearly established. We
show that human B cells from peripheral blood and tonsils
express CXCL16 (Figures 1(a) and 1(b)). Such expression
appearshigherintheperiphery(Figure 1(a):leftpanel)when
compared to tonsillar B cells (Figure 1(a): right panel).
Expression of CXCL16 on B cells does not appear to depend
on the maturational stage, as na¨ ıve CD21hi CD27−IgD+,
nonswitched CD21hi CD27+IgD+, and switched CD21hi
CD27+IgD− B cells express this protein (Figure 1(c)).
3.2. CXCL16 Expression Is Reduced on CVID B Cells. We
then evaluated the expression of CXCL16 on CVID B cells.
Figure 2 shows a representative experiment of B cell CXCL16
expression confronting a healthy control (HD) and a CVID
patient: the expression of CXCL16 is evidently reduced in the
CVID patient (Figure 2(a)). Figure 2(b) shows the mean of
10 healthy controls and 10 CVID patients. The percentage
of peripheral B cells from CVID patients expressing CXCL16
was signiﬁcantly lower than in age-matched healthy controls
(70%versus38.1%,P = 0.0277)(Figure 2(b)).Furthermore,
the mean ﬂuorescence intensity of CXCL16 expression at the
cellsurfacewasalsoreducedinCVIDpatientsversuscontrols
(MFI: 14.3 versus 34.4, resp., P<0.001) (Figure 2(c)).
Direct gene sequencing of the CXCL16 gene was performed
in order to evaluate whether the reduced surface expression4 The Scientiﬁc World Journal
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Figure 2: CXCL16 expression in CVID. (a) Reduced expression of CXCL16 on CVID B cells (representative experiment). (b) Mean of
CXCL16+ B cells in healthy controls (number = 8) and CVID patients (number = 10). (c) Mean ﬂuorescence intensity of CXCL16 on CD19+
B cells in cells in healthy controls (number = 10) and CVID patients (number = 10) (values expressed in mean). Graph bars show standard
error (SE). (d) mRNA levels of CXCL16 from healthy controls and CVID patients.
of the CXCL16 protein was due to genetic alterations. Seven
already reported SNPs (rs2250333, rs1051009, rs1050997,
rs2277680, rs2304970, rs10509989, and rs1876444) were
found in diﬀerent combinations among the CVID patients.
The allelic frequencies of these variants in CVID patients
were similar to those observed in healthy controls (data not
shown). Furthermore, CXCL16 mRNA expression levels
were similar between CVID patients and healthy controls
(Figure 2(d)).
3.3. CXCL16 and CpG. Since CXCL16 expression has been
reported to inﬂuence immune cell responses after CpGThe Scientiﬁc World Journal 5
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Figure 3: Defective upregulation of activation markers (CD69, CD86) after in vitro stimulation with CpG in CVID. (a) Fold increase in
CD69 expression in healthy controls and CVID patients CVID (mean of six and ﬁfteen samples, resp.). (b) Fold increase in CD86 expression
in healthy controls and CVID patients (mean of six and ﬁfteen samples, resp.). Graph bars show standard error (SE).
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Figure 4: Defective upregulation target genes (mRNA levels) after in vitro stimulation with CpG in CVID. (a) Fold increase of CD69, CD86,
TLR9, AICDA, and IL-6 at the mRNA level after CpG stimulation. Experiments were performed with PBMCs in triplicates for all patients
(n = 15) and healthy controls (n = 8). (b) Fold increase of TLR9, AICDA, and IL-6 at the mRNA level after CpG stimulation. Experiments
were performed with puriﬁed B cells from patients (n = 4) and healthy controls (n = 2). Graph bars show standard error (SE).
stimulation [16], we decided to investigate whether the
reduced CXCL16 expression on CVID B cells correlated
with speciﬁc biological responses in vitro. To address this
issue, PBMCs were incubated with CpG and tested for
upregulation of the activation markers CD69 and CD86 after
24 hours of incubation (Figure 3(a)). CVID B cells presented
a signiﬁcant defect in CD69 upregulation after CpG in vitro
stimulation: the mean fold increase in MFI was 59.4% lower
than in healthy controls (4.54 versus 7.64, resp.). Similar
ﬁndings were observed when the upregulation of CD86
after in vitro CpG stimulation was tested (Figure 3(b)): the
mean fold increase in MFI was 58.7% lower than in healthy
controls (3.47 versus 5.97, resp.).
B cell responses to CpG may also be measured by mRNA
upregulation of speciﬁc target genes such as TLR9, AICDA,
IL-6, CD69,a n dCD86. We therefore performed Real-Time
PCR for the above mentioned genes after CpG in vitro
stimulation for 24 hours (Figure 4(a)). TLR9 upregulation
wassimilarbetweenhealthycontrolsandCVIDpatients(P =
0.7073-n.s). However, we observed a statistically signiﬁcant
diﬀerence in the upregulation of CD69, CD86, AICDA, and
IL-6; in particular, CVID B cells fail to up-regulate CD69,
CD86, AICDA, and IL-6 mRNA after CpG stimulation when
compared to healthy controls (61%, 59%, 49%, and 43%
reducedupregulation,resp.).Theseresultswereconvalidated
by performing the same experiment with puriﬁed peripheral
B cells from healthy controls and CVID patients with similar
results (Figure 4(b)).
3.4. CXCL16high BC e l l si nC V I D .During our evalua-
tion of CXCL16 expression, we identiﬁed the presence of
CXCL16high expressingBcellsinCVID.Figure 5(a)showsthe
elevatedexpressionofCXCL16ontheperipheralBcellsfrom
the CVID patient (Patient 10; see Table 1) when compared
to the healthy control. We then compared the expression
of CXCL16 between the CXCL16high CVID patient, eight
healthy controls and ten CVID patients (Figure 5(b)). The
totality of the CXCL16high CVID B cells express CXCL16,
while such percentage is around 70% for healthy controls
and is further reduced in CVID patients (40%) (Figure 5(b)
left panel). Interestingly, the mean ﬂuorescence intensity
is particularly elevated in this patient: more than 10-fold6 The Scientiﬁc World Journal
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Figure 5: Identiﬁcation of CXCL16high B cells. (a) Elevated expression of CXCL16 on CVID B cells when compared to healthy control. (b)
Elevated expression of CXCL16 on CVID B cells when compared to the mean expression levels of CVID patients and healthy controls both
as percentage (left panel) and mean ﬂuorescence intensity (right panel). (c) Characterization of maturational status of CXCL16high Bc e l l sb y
expression of CD27, IgD, and CD19, CD21. Graph bars show standard error (SE).
when compared to healthy controls and almost 29-fold when
comparedtotheCVIDpatients(420versus40forthehealthy
controls and 15 for the CVID patients) (Figure 5(b) right
panel).
Furthermore, we tried to better characterize the mat-
urational state of the CXCL16high B cells by multicolor
ﬂow-cytometry (Figure 5(c)). We found that these cells
present defective peripheral maturation as they only present
the CD27+IgD+ population. Interestingly, the totality of
CXCL16high B cells is CD19hiCD21low (Figure 5(c) right
panel) conﬁrming the presence of this B cell subset in
patientswithautoimmunephenomena(CVIDpatientaffect-
ed with autoimmune enteropathy).
3.5. CXCL16high Expression on CVID B Cells Evokes a Vigorous
Response to CpG. The identiﬁcation of the CXCL16highThe Scientiﬁc World Journal 7
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Figure 6: CXCL16high B cell responses to CpG. (a) Evaluation of target gene (mRNA levels) upregulation (mRNA levels) after in vitro
stimulation with CpG. Fold increase of CD69, CD86, TLR9, AICDA, and IL-6 at the mRNA level after CpG stimulation. Experiments were
performed with PBMCs in triplicates for all patients (n = 15) and healthy controls (n = 8). (b) Fold increase of TLR9, AICDA, and IL-6 at
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Graph bars show standard error (SE). (c) Evaluation of target gene (mRNA levels) upregulation (mRNA levels) after TNF-α blockade and
in vitro stimulation with CpG. Fold variation of CD69, CD86, TLR9, AICDA, and IL-6 at the mRNA level is showed. Experiments were
performed with PBMCs in triplicates for all patients (n = 15) and healthy controls (n = 8). Graph bars show standard error (SE).
B cell population in CVID led us to investigate their in vitro
responses to CpG stimulation and compare them with those
from healthy controls and CVID patients with low CXCL16
expression (Figures 6(a) and 6(b)).
CXCL16high CVID B cells presented a higher upregula-
tion of CD69 and CD86 when compared to CVID patients
with low CXCL16 expression (2.2 and 1.8 fold, resp.);
interestingly, such upregulation was similar to that observed
in healthy controls (Figure 6(a)).
Surprisingly, CXCL16high B cells showed a vigorous re-
sponsetoCpGstimulationasdeﬁnedbyupregulationofIL-6
andTLR9mRNAwhencomparedtoCVIDpatientswithlow
CXCL16 expression (2.9 and 1.9 fold, resp.) and to healthy
controls (1.65 and 1.55 fold, resp.) (Figure 6(a)). AICDA
mRNA levels were lower in CXCL16high B cells after CpG
stimulation. These results were convalidated by performing
the same experiment with puriﬁed peripheral B cells from
healthy controls and CVID patients with similar results
(Figure 6(b)). Inﬂammatory and autoimmune phaenomena
are frequently treated with monoclonal blocking antibodies
to TNF-α (Inﬂiximab) in CVID (21–24). Considering the
clinical data (CVID patient with enteropathy), we tested
whether the vigorous responses of the CXCL16high Bc e l l s
were dependent on TNF-α.T N F - α blockade abrogated B
cell responses to CpG. More in detail, we noticed a 4.3 fold
reduction in the up-regulation of CD69 mRNA, and more
than 5-fold reduction in the up-regulation of IL-6 and TLR9
(5.8 and 5.25 fold, resp.). Reduction in CD86 and AICDA
up-regulation was less signiﬁcant, but still present (1.4 fold
each) (Figure 6(c)).
4. Discussion
Common variable immunodeﬁciency (CVID) is a complex
disorder where little is known on the biological mechanisms
underlying B cell defective responses. Genetic studies in8 The Scientiﬁc World Journal
the last years have shed light in the genetic causes of a limited
number of CVID patients (10–12%) [6–12]. The genetic
defects so far identiﬁed are B cell speciﬁc with the exception
of ICOS deﬁciency. On the other hand, components of
the innate immunity, in particular the family of Toll-like
receptors (TLRs), were recently linked to the homeostasis
of the adaptive arm of the immune system. TLR9 signalling
in particular has been shown to be important for B cell
activation and maturation [13]. Defects in the TLR9 sig-
nallingpathwayafterCpGstimulationwererecentlyreported
in CVID patients [14, 15] conﬁrming such link. CXCL16,
a membrane bound scavenger receptor, has been shown to
inﬂuence responses to CpG [16]. CXCL16 expression has
been described on macrophages, dendritic cells, podocytes,
epithelial cells, tumor cells; however, the expression of
CXCL16 on B cells is not well established yet. We show
that CXCL16 is normally expressed on primary B cells,
both from healthy tonsils and peripheral blood. We describe
the reduced expression of CXCL16, both as percentage and
mean ﬂuorescence intensity, on a group of CVID patients’
B cells to be associated with defective in vitro responses
to CpG. Direct gene sequencing of the CXCL16 encoding
gene evidenced the presence of seven already reported SNPs
at similar allelic frequencies as found in healthy controls;
such mutations did not aﬀect the mRNA levels. We also
show that CXCL16 is normally expressed during all stages
of peripheral B cell maturation, suggesting that the reduced
expression in CVID is not related to the altered peripheral B
cell diﬀerentiation, a hallmark of CVID. It is well known that
in CVID, T and B cell interactions may be altered causing
defective/altered germinal center reaction, thus resulting in
defective generation of memory B cells and plasma cells [1,
3–5]. Since CXCL16 is a strong chemoattractant for CXCR6
expressing T cells, it could be hypothesized that reduced
expression of CXCL16 on CVID B cells may inﬂuence in
a negative manner the crosstalk between T and B cells in
CVID. Further studies will be needed to address this issue.
In addition, CXCL16 has been shown not only to recruit
activated T lymphocytes but also to play a direct role in the
binding and phagocytosis of bacteria (both Gram-positive
and Gram-negative ones) by professional antigen-presenting
cells [21, 22]. It can be therefore proposed that low CXCL16
expression on CVID B cells may contribute to noneﬀective
clearance from bacterial infections, another hallmark of
CVID.
The correlation between B cell CXCL16 expression levels
and B cell responses to CpG was further underlined by
the identiﬁcation of CVID B cells with high expression
levels of CXCL16 (CXCL16high). These CXCL16high Bc e l l s
express the protein with a mean ﬂuorescence intensity
almost 30-fold superior to that observed in other CVID
patients. CXCL16high B cells appear to be associated with
autoimmune phenomena in CVID [23–26], autoimmune
enteropathy in our case. Interestingly, CXCL16high B cells are
exclusively CD19hiCD21low, conﬁrming the role of this B cell
subpopulation in autoimmune manifestations. CXCL16high
B cells showed a vigorous response to CpG stimulation
in vitro, for some aspects even superior to healthy con-
trols (IL-6 and TLR9 upregulation). Moreover CXCL16high
B cells are associated with autoimmune and inﬂammatory
phaenomena and show a vigorous response to CpG in a
TNF-α dependent manner. It appears therefore plausible
that CXCL16 may become an additional marker for B cells
in CVID patients with autoimmune and inﬂammatory
phaenomena, together with CD21low.
In conclusion, we report that the expression levels of
CXCL16 on B cells can predict the extent of B cell responses
toCpGinCVIDpatients.ThereducedexpressionofCXCL16
on B cells correlates with defective cell activation; on the
other hand, elevated expression levels of CXCL16 on B cells
(CXCL16high)correlateswithavigorousresponsetoCpGand
appear to be associated with autoimmune and inﬂammatory
phaenomena, at least in our case. It is evident that a larger
number of CVID patients with autoimmune phaenomena
needs to be tested to further conﬁrm this ﬁnding.
To our knowledge, this constitutes the ﬁrst report
which links the expression levels of a surface receptor with
the cell responses mediated by an intracellular TLR and
is associated with a disease in humans, namely, common
variable immunodeﬁciency.
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